The biopharmaceutical firm reports a wider-than-expected per-share loss for the quarter, missing analyst estimates.
Neumora Therapeutics reported a GAAP loss of $0.30 per share for the quarter, reflecting higher research and development expenses. The figure underscores the company’s heavy investment in clinical-stage programs targeting neurological and psychiatric disorders.
Analysts had anticipated a narrower loss, with consensus estimates closer to $0.25 per share. In the same period last year, the company posted a loss of $0.22 per share, indicating an accelerated burn rate as it advances its pipeline.
Shares showed limited movement in after-hours trading, as investors weighed the loss against long-term growth potential in the neuroscience sector.